Literature DB >> 12547507

Neutralizing antibodies in gene-defective hosts.

Ghislain Opdenakker1, Philippe E Van den Steen, Geneviève Laureys, Kathleen Hunninck, Bernd Arnold.   

Abstract

In a host with a normal immune system and a complete gene defect, the nondefective gene product will be immunogenic. Consequently, neutralizing antibodies against the respective protein can arise either 'spontaneously' or after immunization, as shown in patients and in animal models, such as knockout mice. Accordingly, patients with X-linked or homozygous autosomal gene defects are at risk of developing neutralizing antibodies, in particular after protein substitution or gene therapy. This Review compares and exemplifies the various genetic and immunological contexts that lead to 'neutralizing and generated by gene defect' or 'nagged' antibodies, and outlines implications and solutions for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547507     DOI: 10.1016/s1471-4906(02)00037-6

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  3 in total

1.  Inhibitory Monoclonal Antibodies against Mouse Proteases Raised in Gene-Deficient Mice Block Proteolytic Functions in vivo.

Authors:  Ida K Lund; Morten G Rasch; Signe Ingvarsen; Jesper Pass; Daniel H Madsen; Lars H Engelholm; Niels Behrendt; Gunilla Høyer-Hansen
Journal:  Front Pharmacol       Date:  2012-06-28       Impact factor: 5.810

Review 2.  How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?

Authors:  Ghislain Opdenakker; Séverine Vermeire; Ahmed Abu El-Asrar
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

3.  Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.

Authors:  Magali de Bruyn; Christine Breynaert; Ingrid Arijs; Gert De Hertogh; Karel Geboes; Greet Thijs; Gianluca Matteoli; Jialiang Hu; Jo Van Damme; Bernd Arnold; Marc Ferrante; Séverine Vermeire; Gert Van Assche; Ghislain Opdenakker
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.